Fimlab Laboratoriot Oy

What Fimlab Laboratoriot Oy does

Fimlab Laboratoriot Oy is Finland's largest healthcare laboratory company, owned by five wellbeing services counties (Pirkanmaa, Kanta-Häme, Keski-Suomi, Päijät-Häme, and Ostrobothnia), with three additional counties and the NordLab welfare association as minority shareholders. Headquartered in Tampere and founded in 2011, the company operates approximately 1,100 professionals delivering 16.5 million examinations and 3.3 million sampling occasions annually across more than 100 service locations. Its scope spans clinical chemistry, hematology, microbiology, pathology, genetics, and fertility treatment laboratory services, plus designated national responsibility for colorectal and cervical cancer screening programs. In 2025, Fimlab reported revenue of EUR 173.5 million with operating profit of EUR 3.8 million (approximately 2.2% margin), reflecting the cost-constrained nature of publicly-funded laboratory services.

The company's product portfolio combines traditional laboratory diagnostics with a growing digital layer: the Fimlab Mobile Application for patient results, the Vihta appointment booking platform, Nopsa walk-in rapid blood testing, automated sample container machines deployed in Ylöjärvi and Äänekoski, and the OmaLabra private-customer channel. In 2024, Fimlab adopted Proscia's AI-powered digital pathology software to enhance cancer diagnosis precision, and in 2025-2026 it integrated screening results into the national MittKanta patient record system with electronic delivery via Suomi.fi and OmaPosti. Additional services include remote STD testing, the Pikku-Labbis pediatric phlebotomy support program, diabetes equipment management for multiple counties, and a Tampere-based fertility treatment laboratory. The company is accredited to SFS-EN ISO 15189:2022 for medical laboratories and is GDPR-compliant with multiple named privacy registers.

Fimlab operates a B2B2C revenue model, with wellbeing services counties funding laboratory services through public healthcare budgets (subscription/recurring revenue), complemented by direct-pay services for private individuals at publicly-listed prices (e.g., sperm analysis at EUR 85, sterilization control at EUR 103, plus a EUR 7.55 service fee). Customer satisfaction is tracked via Net Promoter Score, reaching 89 based on approximately 1,500 evaluations in May 2026. The GTM motion combines direct enterprise relationships with public healthcare systems and self-serve digital channels for private customers, supported by marketing across website, Instagram, Facebook, YouTube, LinkedIn, and a Spotify-hosted Fimlab podcast.

Name

Fimlab Laboratoriot Oy

Legal name

Fimlab Laboratoriot Oy

Website

https://fimlab.fi

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Fimlab Laboratoriot Oy is Finland's largest healthcare laboratory company, owned by five wellbeing services counties. It provides clinical diagnostics, pathology, genetics, fertility services, and national cancer screening across 100+ service locations, serving both public healthcare systems and private customers.

Ownership category

akta.pro rank

Headquarters

HQ city

Tampere

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Public Healthcare Laboratory Services: Fimlab is owned by wellbeing services counties and provides laboratory services funded through public healthcare budgets. Services are provided to Pirkanmaa, Kanta-Häme, Keski-Suomi, Päijät-Häme, and Ostrobothnia regions.
2. Private Customer Services: Private individuals can access laboratory services with or without referral, including pricing for specific tests such as semen analysis.
3. National Cancer Screening Services: Functions as a national screening center for colorectal cancer and cervical cancer screening across Finland.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Fimlab Laboratoriot Oy provides healthcare laboratory diagnostic services across clinical chemistry, hematology, microbiology, pathology, genetics, and fertility treatment. The company operates over 100 service locations serving five Finnish wellbeing services counties, performing 3.3 million sampling occasions and 16.5 million examinations annually. Services also include national colorectal and cervical cancer screening programs, digital results delivery via mobile app, and AI-powered cancer diagnostics.

Product overview

Fimlab Laboratoriot Oy is Finland's largest healthcare laboratory company, owned by wellbeing services counties, providing laboratory diagnostic services across Pirkanmaa, Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia through over 100 service locations with approximately 1,100 professionals. The company's product portfolio centers on its core laboratory testing services (3.3 million sampling occasions and 16.5 million examinations annually) complemented by digital health offerings including the Fimlab Mobile Application for viewing laboratory results, the Vihta appointment booking system, and Nopsa rapid blood testing. Additional services include OmaLabra private healthcare channel, automatic sample container machines, remote STD testing, fertility treatment laboratory with sperm analysis, diabetes equipment management, and national cancer screening programs (colorectal and cervical). The company has adopted AI-powered digital pathology software (Proscia) for enhanced cancer diagnostics, and supports children's phlebotomy through the Pikku-Labbis program.

Differentiator

Problem solved

Functional benefit

Products and services

• Fimlab Mobile Application Mobile application enabling users to view common laboratory test results on their mobile phone with strong authentication. Results are available for most common laboratory tests with up to two-year history, color-coded by reference range, and shared with treating healthcare provider.
• Nopsa Rapid Blood Testing Rapid blood testing service allowing walk-in blood tests without appointment or queue number at designated service points for quick sample collection.
• OmaLabra Private Healthcare Channel Private healthcare service channel allowing customers to access certain laboratory services outside the public healthcare system.
• Automatic Sample Container Collection and Return Machine Automated system for collecting and returning urine sample containers, enabling easy and quick sample handling for patients. Deployed at service points in Ylöjärvi and Äänekoski.
• Remote STD Testing Free remote testing service for chlamydia and gonorrhea using urine or vaginal samples. Available in Tampere, Päijänne-Tavastland, Central Finland, and Österbotten. Test kits ordered online, samples taken at home and mailed to laboratory, results received via app or MittKanta.
• Fertility Treatment Laboratory Laboratory providing wide range of fertility treatment services including sperm analysis, frozen embryo storage, and maintenance of donated gamete bank. Located at Tampere central laboratory.
• Sperm Analysis Semen analysis examining sperm volume, density, total count, motility, and presence of sperm antibodies. Also includes post-sterilization verification. Available by appointment only at Tampere fertility treatment laboratory. Priced at EUR 85 (+ service fee EUR 7.55) for private customers.
• Diabetes Equipment Services Competitive procurement and management of diabetes equipment and supplies including blood glucose meters, continuous glucose monitoring systems, and insulin pumps for wellbeing services counties in Central Finland, Pirkanmaa, and Kanta-Häme.
• Colorectal Cancer Screening National colorectal cancer screening program using FIT-test (fecal immunochemical test) to detect hidden blood in stool. Available for residents aged 56-74 (in 2026, ages 60, 62, 64, 66, 68, 70, 72). Samples collected at home and mailed to laboratory for analysis.
• Cervical Cancer Screening National cervical cancer screening program for early detection of precancerous changes and cancer. Electronic invitations, reminders, and results delivered via Suomi.fi messages and OmaPosti from September 17, 2025. Results registered in MittKanta from March 9, 2026.
• AI-Powered Digital Pathology (Proscia) AI-powered digital pathology software platform from Proscia for enhanced cancer diagnosis. Uses computer vision to analyze histopathology tissue slide images and supports consistent interpretations of cancer cases. Integrates precision medicine AI applications.
• Vihta Appointment Booking System Online appointment booking platform for scheduling laboratory visits. Accessible at fimlab.vihta.com with separate accessibility statement.
• Pikku-Labbis Children's Phlebotomy Support Child phlebotomy support program helping children prepare for laboratory visits. Includes educational videos, picture books, and numbing cream recommendations to reduce fear and anxiety.

Quantifiable outcome

• 16.5 million examinations performed annually
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability2 records

Feature1 record

Partnerships

One partnership is on record.

• ProsciacoreTechnology or Integration · 12 September 2024Fimlab has adopted Proscia's AI-powered digital pathology software platform to enhance pathologists' ability to deliver more precise cancer diagnoses. The software enables consistent interpretations of cancer cases and integrates applications from Proscia's precision medicine AI portfolio, positioning Fimlab at the forefront of AI-enabled pathology.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Synlab: Europe's largest medical diagnostics services provider offering clinical laboratory, imaging, and specialty testing services across multiple countries. A broad incumbent with overlapping service portfolio to Fimlab's centralized lab model.
• Quest Diagnostics: One of the largest clinical laboratory networks in the US offering routine testing, esoteric diagnostics, and pathology services. Comparable business model to Fimlab's centralized lab services with similar service mix.
• Sonic Healthcare: Global medical diagnostics company operating in Australia, Europe, and North America with laboratory and pathology services. Comparable as a large-scale diagnostics operator with a similar service mix to Fimlab.
• Amedes: European medical diagnostics company offering laboratory, pathology, and imaging services across multiple European countries. Comparable in service breadth to Fimlab's comprehensive diagnostic offering.
• Labcorp: Major US clinical laboratory services company with comprehensive testing capabilities across routine, specialty, and pathology diagnostics. Comparable to Fimlab in centralized lab business model and service breadth.
• Unilabs: Major European diagnostics provider offering clinical laboratory, imaging, and pathology services across multiple countries. Comparable to Fimlab in service scope and in operating a hybrid public-private model.

Regional players

• Terveystalo: Finland's largest private healthcare services company with primary care, specialist care, and laboratory operations. Competes with Fimlab in private laboratory services in Finland, particularly in occupational health and direct-pay testing.
• Mehiläinen: Major Finnish private healthcare and social services provider with diagnostic and laboratory operations. Competes with Fimlab in private healthcare laboratory services in Finland.

Direct peers

• NordLab: Nordic medical laboratory company serving northern Sweden and a minority shareholder of Fimlab. Provides hospital laboratory services with a similar public healthcare funding model and comparable regional scale.
• HUSLAB: Helsinki University Hospital's laboratory division serving the Uusimaa region of Finland. The most direct competitor to Fimlab in the Finnish public healthcare laboratory market, with similar scope of clinical chemistry, pathology, and genetics services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@fimlablaboratoriot
• Facebookfacebook.com/fimlab
• LinkedInlinkedin.com/company/fimlab-laboratoriot-oy
• Instagraminstagram.com/fimlab

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fimlab Laboratoriot Oy